{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"123","value":"45.7"},{"groupId":"OG001","spread":"122","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"title":"Cycle 1 Day 1 (within 2 to 4 hours postdose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"76","value":"76"},{"groupId":"OG001","spread":"103","value":"64.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (Predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70","value":"141"},{"groupId":"OG001","spread":"73","value":"144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Cycle 3 Day 1 (3 hours post-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69","value":"136"},{"groupId":"OG001","spread":"69","value":"146"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Cycle 3 Day 1 (5 hours post-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69","value":"85.2"},{"groupId":"OG001","spread":"97","value":"63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Cycle 4 Day 1 (Predose)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"* Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing.\n* For Cycle 1 Day 1, sampling occurred at a \"single\" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Arm A: Imlunestrant"},{"description":"Participants received Imlunestrant 400 mg orally once daily on Days 1 to 28 of a 28-day cycle, plus Abemaciclib 150 mg orally twice daily on Days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation was met.","id":"OG001","title":"Arm C: Imlunestrant + Abemaciclib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomised participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)","title":"Pharmacokinetics (PK): Plasma Concentration of Imlunestrant","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter"}